LLY has been in an uptrend, fueled by a good Q3 earnings report, an upbeat forecast for 2019, and strong top-line data from a key clinical trial.
This article reviews the clinical trial in detail and explains its potential importance.
Attention is also paid to LLY's GAAP versus non-GAAP earnings as well as naming having David Ricks in the company's three top positions.
I am (not for the first time) treating LLY in the current price range as a short-term momentum play that has too many issues to be a strong long term buy until the price declines.
Last October 8, I wrote my first article focusing on Eli Lilly (LLY), Eli Lilly Surges On Pipeline News: Analysis And Trading Thoughts. My analysis was that the company was doing